Skip to main content
Caplight Logo









Alveus Therapeutics

Alveus Therapeutics

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://alveustx.com/

Last Round

Series A

Extension

Feb 24, 2026

Total Funding Raised

$234M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Alveus Therapeutics is a biotechnology company developing next-generation therapies for obesity and metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryobesity treatmentmetabolic diseasebiotechclinical-stage biotechtherapeutic developmentGLP-1weight loss drugpharmaceutical R&Ddrug pipelinebiopharmaclinical triallicensing agreement

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Alveus Therapeutics Comparables

Compare Alveus Therapeutics with similar companies based on industry and business-model similarity.

Alveus Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Verdiva Bio
86%
Antag Therapeutics
85%
Pep2Tango Therapeutics Inc.
85%

Alveus Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionFeb 24, 2026
Series AJan 8, 2026

Alveus Therapeutics Investors

Notable investors and investment history

Alveus Therapeutics investors
InvestorRounds
Avego ManagementSeries A, Series A Extension
Omega FundsSeries A, Series A Extension
Andera PartnersSeries A, Series A Extension
New Rhein Healthcare InvestorsSeries A, Series A Extension
Novo HoldingsSeries A Extension
Sanofi VenturesSeries A Extension
Jeito CapitalSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 19, 2026

    Monthly visitors increased 40% MoM.

  • Jun 4, 2026

    Grew 22% QoQ, from 27 to 33 employees.

Alveus Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Alveus Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Alveus Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range34
Year Founded2024
Last FundingFeb 24, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?